Speedy FDA approval puts Stehlin anticancer drug in clinical trials
Breast cancer patients are risking their lives by failing to take the tamoxifen they are prescribed, according to a new study published in the British Journal of Cancer.Half of the women failed to finish a five year course of the drug and one in five regularly forget to take a tablet.Experts already know that taking
Full Post: Women risk their lives by failing to take breast cancer drugs
A promising anticancer drug developed by the Christus Stehlin Foundation for Cancer Research in Houston is being tested on patients after quickly receiving approval from the U.S. Food and Drug Administration for Phase I clinical trials.
Generally, only five potential anticancer drugs out of every 5,000 to 10,000 developed are approved by the FDA for Phase 1 trials.
The drug, CZ48, is derived from a Chinese tree, Camptotheca, whose anticancer potential was discovered in the 1960s.
The Stehlin Foundation has been researching cancer treatment with compounds of the Camptothecin family since 1988.
--------------------------------------------------------------------------------------------Related Posts:
The Cure Our Children Foundation, a nonprofit charitable foundation dedicated to children, announced today that the U.S. Food and Drug Administration (FDA) has approved the Orphan Drug Designation of the foundation’s unique drug product for children with Ewing’s Sarcoma cancer. The efforts to develop this drug were made possible by the generous volunteers and researchers
Full Post: FDA grants orphan drug status to new ‘Trojan Horse’ like Ewing’s Sarcoma drug
--------------------------------------------------------------------------------------------
- A huge study funded by the National Institutes of Health triples the number of genes linked to lung cancer and points toward new treatments. The study analyzed DNA sequences from 623 genes in tumor samples from 188 patients with lung adenocarcinoma, the most common form of lung cancer. The study turned up 26 genes mutated at
Full Post: Lung Cancer Genes Raise Treatment Hopes
--------------------------------------------------------------------------------------------
Gemin Xsecured a patent from the U.S. Patent and Trademark Office protecting the composition of matter of Obatoclax, its lead new drug candidate, through 2025. Obatoclax is an experimental oncology treatment based on programmed cell death — a process known as apoptosis. The new drug candidate, according to Gemin X, has the potential to be a “first-in-class
Full Post: Gemin X gets patent for experimental cancer treatment
--------------------------------------------------------------------------------------------
Olives are one of the oldest foods known to man, dating back some thousands of years in the Mediterranean region. The olive tree was valued as a symbol of peace and happiness and is well-known as a blessed tree. While olives were used as food, olives leaves are widely used for medicinal values and, olive
Full Post: Olives - A Superb Nutrition to Mankind
--------------------------------------------------------------------------------------------
CHCIAGO, Nov. 17 — For carefully selected Asian patients with non-small-cell lung cancer, the tyrosine kinase inhibitor gefitinib (Iressa) significantly improved progression-free survival compared with the standard carboplatin (Paraplatin) and paclitaxel (Taxol), researchers reported here. The phase III IRESSA-Pan Asia Study (IPASS) included patients who were chemotherapy na?ve, were never smokers or light smokers with
Full Post: CTS: Gefitinib Superior to Chemotherapy Among Asians with Lung Cancer